357
Participants
Start Date
December 31, 2011
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
Placebo
matching placebo to RO4995819 oral once daily for 6 weeks
RO4995819
5 mg oral once daily for 6 weeks
RO4995819
15 mg oral once daily for 6 weeks
RO4995819
30 mg oral once daily for 6 weeks
Vienna
Wien, Vienna
Innsbruck
Cape Town, Western Cape
Bellville, Cape Town
Cape Town, Western CAPE
New York
New York
New York
Rochester
Oranienburg
Jenkintown
Schwerin, Mecklenburg-Vorpommern
Media
Vinnytsia
Baltimore
Richmond
Roanoke
Durham
Columbia
Roswell
Smyrna
Atlanta
Jacksonville
Gainsville
Coral Springs
North Miami
Lauderhill
Ocala
Flowood
Beachwood
Canton
Cincinnati
Cincinnati
Dnipropetrovsk
Kharkiv
O'Fallon
Odesa
Prairie Village
Wichita
Mannheim
Ellwangen
Kherson,Vil. Stepanivka
Ostfildern
Arlington
Houston
Denver
Donetsk
Salt Lake City
Phoenix
Albuquerque
Nuremberg
Torrance
San Diego
Victorville
Redlands
Stanford
Oakland
Simferopol, Crimea
Moscow
Moscow
Yaroslavl
Talagi
Saint Petersburg
Saint Petersburg
Saint Petersburg
Saint Petersburg
Smolensk
Lipetsk
Samara
Yekaterinburg
Yekaterinburg
Novosibirsk
Tomsk
Chicago
Boston
Watertown
Kentville
Kingston
Ottowa
Gatineau
Sherbrooke
Verdun
Leipzig
Bratislava
Bratislava
Bratislava
Rimavská Sobota
Trenčín
Centurion, Pretoria
Nieu Muckleneuk, Pretoria
Kiev
Hoffmann-La Roche
INDUSTRY